NSE: BALAXI · PHARMACEUTICALS

BALAXI PHARMACEUTICALS LIMITED Share Price & Company Info

₹22.06-5.89%

End-of-day price, · Educational content, not investment advice

52W low ₹15.2052W high ₹43.85
Market cap
₹106 Cras reported by NSE
52-week high
₹43.8504-NOV-2025
52-week low
₹15.2027-MAR-2026
P/E (NSE)
43.61
Face value
₹2.00
Shares issued
5,52,07,500
Volume
16,771₹0.04 Cr traded
Delivery
92.59%of traded quantity
Price band
20%₹15.77 – ₹23.65 on 2026-11-02
Annual volatility
54.26%NSE, from daily returns
Series
EQrolling settlement
ISIN
INE618N01022
Listed on NSE
30-Nov-2015

About BALAXI PHARMACEUTICALS LIMITED

BALAXI PHARMACEUTICALS LIMITED is listed on the National Stock Exchange of India under the symbol BALAXI in the EQ series. NSE classifies it under the basic industry Pharmaceuticals, part of the Healthcare sector. Its shares were listed on NSE on 30-Nov-2015. Each share has a face value of ₹2.00.

In the end-of-day data for 16 November 2026 the stock closed at ₹22.06, down 5.89% on the day. NSE puts the company's market capitalisation at about ₹106 crore, which puts it among the smallest listed companies in India. Over the past 52 weeks it has traded between ₹15.20 and ₹43.85, so the last price is 45.1% above the low and 49.7% below the high.

16,771 shares changed hands that day, and 92.59% of them were taken as delivery rather than squared off intraday. A high delivery share means most of the day's buyers chose to hold the shares; a low one usually means the volume was mostly short-term trading.

EQ is the normal equity series: shares settle on the usual T+1 cycle and intraday trading is allowed.

NSE currently lists a regulatory note for this stock: “Less than 100 unique PAN traded in prev. 30 days | High low price var. was greater than 150% in prev. 12 mths”. Notes like these come from the exchange's surveillance and disclosure checks and can mean higher margins, trade-for-trade settlement or limits on trading. Check the NSE quote page for the current position before trading.

NSE puts the stock's annualised volatility at 54.26%. That is well above the level of large, established companies, so double-digit swings within a month are common.

Because the share trades below ₹30, it also appears in our list of penny stocks under ₹30, which explains the extra risks that come with low-priced shares.

BALAXI PHARMACEUTICALS LIMITED quarterly results

In the quarter ended June 2026 (un-audited), BALAXI PHARMACEUTICALS LIMITED reported total income of ₹16.50 crore and a net loss of ₹1.25 crore, or ₹-0.23 per share.

Compared with the previous quarter (March 2026), income fell 30.1%.

BALAXI PHARMACEUTICALS LIMITED was profitable in 3 of the 4 quarters shown below. Figures are as filed with NSE, in ₹ crore.

Quarterly results filed with NSE (₹ crore, EPS in ₹)
Quarter endedTotal incomeProfit before taxNet profitEPSStatus
June 202616.50-1.12-1.25-0.23Un-Audited
March 202623.610.420.160.03Audited
December 202526.222.121.530.28Un-Audited
September 202523.524.243.260.59Un-Audited

BALAXI PHARMACEUTICALS LIMITED shareholding pattern

At the end of September 2026, promoters and the promoter group held 65.99% of BALAXI PHARMACEUTICALS LIMITED, with the public holding 34.01%. The promoter stake has not changed across the 8 quarterly filings shown, from December 2024 to September 2026.

Shareholding by category, as filed with NSE each quarter
Quarter endedPromoter & Promoter Group (%)Public (%)
September 202665.9934.01
June 202665.9934.01
March 202665.9934.01
December 202565.9934.01
September 202565.9934.01
June 202565.9934.01
March 202565.9934.01
December 202465.9934.01

BALAXI PHARMACEUTICALS LIMITED share price performance

Over the past year the BALAXI PHARMACEUTICALS LIMITED share price has lost 53.46%, against a fall of 10.92% for the NIFTY 50, so it has underperformed that index by 42.54 percentage points.

Across the 7 periods in the table, the stock did not beat the NIFTY 50 in any of them. Past returns describe what happened; they do not predict what comes next.

Price change by period, as of 2026-11-02 (NSE)
PeriodBALAXINIFTY 50
1 month-14.00%+1.91%
3 months-20.07%-5.20%
6 months-26.44%-3.94%
1 year-53.46%-10.92%
2 years-78.23%-5.29%
3 years-76.24%+20.44%
5 years-82.44%+30.45%

BALAXI PHARMACEUTICALS LIMITED vs industry peers

NSE compares BALAXI PHARMACEUTICALS LIMITED with 6 other listed companies in Pharmaceuticals. By market capitalisation it ranks 4 of 7.

Its P/E of 43.61 compares with a median of 22.80 for the other companies in the group: the market is paying considerably more for each rupee of its recent earnings.

NSE industry peer comparison, results for JUN 2026 quarter (₹ crore)
CompanyMarket capPrice (₹)P/EPromoter %Qtr incomeQtr net profit
SOTAC123111.6521.390.00——
KREBSBIO12256.50—72.747.14-2.48
MAKERSL115195.50—0.00——
BALAXI10819.5943.6165.9916.50-1.25
ALPA10750.8024.2157.1929.761.04
VAISHALI87.616.4919.5631.6123.471.49
VILINBIO79.3852.0541.1556.65——

BALAXI PHARMACEUTICALS LIMITED announcements, board meetings and corporate actions

Latest announcements

The most recent filings BALAXI PHARMACEUTICALS LIMITED has made with NSE, newest first:

  • 07-Oct-2026 · Certificate under SEBI (Depositories and Participants) Regulations, 2018: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 (PDF)
  • 07-Oct-2026 · Updates: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended September 2026." (PDF)
  • 06-Oct-2026 · Copy of Newspaper Publication: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication (PDF)
  • 27-Sep-2026 · Trading Window: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 (PDF)
  • 07-Sep-2026 · Updates: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended August 2026 .'. (PDF)
  • 31-Aug-2026 · General Updates: Balaxi Pharmaceuticals Limited has informed the Exchange about the receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation Manufacturing Facility. (PDF)
  • 24-Aug-2026 · Change in Director(s): BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Change in Director(s) of the company. (PDF)
  • 24-Aug-2026 · Shareholders meeting: BALAXI PHARMACEUTICALS LIMITED has submitted the Exchange a copy Srutinizers Report of Annual General Meeting held on 24th August, 2026. Further, the company has informed the Exchange regarding Voting Results. (PDF)

Board meetings

  • 12-Nov-2026 · Financial Results/Other business matters: To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters.
  • 05-Aug-2026 · Financial Results/Other business matters: To consider and approve the unaudited standalone and consolidated financial results of the Company for the first quarter ended 30th June, 2026 of the Financial Year 2026-27, and other business matters.
  • 28-May-2026 · Financial Results/Other business matters: To consider and approve the audited financial results (Standalone and Consolidated) for the fourth quarter and financial year ended March 31, 2026 and other business matters
  • 28-Jan-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended December 31, 2025 and other business matters
  • 11-Nov-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended September 30, 2025 and other business matters

Corporate actions

The corporate actions on record include 1 dividend, 1 share split. The ex-date is the first day the shares trade without the entitlement.

  • Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share · ex-date 30-May-2024 · record date 30-May-2024
  • Annual General Meeting/Dividend - Rs 0.50 Per Share · ex-date 01-Jul-2022 · record date 04-Jul-2022
  • Annual General Meeting · ex-date 21-Sep-2017 · book closure 24-Sep-2017 to 30-Sep-2017
  • Annual General Meeting · ex-date 22-Sep-2016 · book closure 24-Sep-2016 to 30-Sep-2016

Risk notice: low-priced and small-company shares can be illiquid, volatile and subject to manipulation, and shareholders can lose their entire investment. This page is a factual summary, not a recommendation to buy or sell BALAXI PHARMACEUTICALS LIMITED.

Where to find BALAXI PHARMACEUTICALS LIMITED's financials

Direct downloads from NSE:

For full financial statements, shareholding detail and every company announcement, go to the source:

Other Pharmaceuticals stocks on MCX Trends

Frequently asked questions

What is the BALAXI PHARMACEUTICALS LIMITED share price?

BALAXI PHARMACEUTICALS LIMITED (NSE: BALAXI) closed at ₹22.06 in the end-of-day data for 16 November 2026. For a live price, use the NSE quote page or your broker, because this page is updated from end-of-day files.

Which sector does BALAXI PHARMACEUTICALS LIMITED belong to?

NSE classifies BALAXI PHARMACEUTICALS LIMITED under Pharmaceuticals, in the Healthcare sector.

What is the 52-week high and low of BALAXI?

The 52-week high is ₹43.85 (04-NOV-2025) and the 52-week low is ₹15.20 (27-MAR-2026), according to NSE.

Is BALAXI PHARMACEUTICALS LIMITED a penny stock?

At ₹22.06 the share trades below ₹30, so it appears on our list of penny stocks under ₹30. A low share price on its own says nothing about whether a company is cheap or expensive; market capitalisation, debt, profits and exchange surveillance status matter far more.

What is the promoter holding in BALAXI PHARMACEUTICALS LIMITED?

Promoters and the promoter group held 65.99% of BALAXI PHARMACEUTICALS LIMITED at the end of September 2026, according to the shareholding pattern filed with NSE.

What were BALAXI PHARMACEUTICALS LIMITED's latest quarterly results?

For the quarter ended June 2026, BALAXI PHARMACEUTICALS LIMITED reported total income of ₹16.50 crore and a net loss of ₹1.25 crore (EPS ₹-0.23).

Where can I find BALAXI PHARMACEUTICALS LIMITED's annual report and financial results?

Annual reports, quarterly results and other filings are published on the NSE corporate filings pages (search for BALAXI). Screener also lays out several years of financial statements in one place. Links to all of these are above.

More on MCX Trends